In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET
Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.Peer-Reviewed Original ResearchConceptsHealthy male controlsPositron emission tomographyMultilinear analysis 1Antipsychotic treatmentLower BPFrontal cortexReceptor availabilityAge-matched healthy male controlsDifferent second-generation antipsychoticsSteady-state troughPeak serum levelsSecond-generation antipsychoticsPotential therapeutic targetMale patientsSerum levelsHealthy humansTherapeutic targetSchizophrenia patientsTime-activity curvesMale controlsCognitive impairmentEmission tomographyVentral striatumPatientsSchizophrenia20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME
Radhakrishnan R. 20. ELUCIDATING THE LINK BETWEEN CANNABIS USE AND PSYCHOSIS: FROM THE EXPOSOME AND PHENOME TO THE EPIGENOME AND RECEPTOME. Schizophrenia Bulletin 2019, 45: s121-s121. PMCID: PMC6455407, DOI: 10.1093/schbul/sbz022.079.Peer-Reviewed Original ResearchFirst-episode psychosisCannabis useReceptor availabilityEU-GEIMeasures of information processingHealthy controlsEU-GEI studyCannabis use resultsPsychosis-spectrum disordersCannabis use disorderPhenotype of schizophreniaRelevant to psychosisRegular cannabis useBrain imaging studiesAssociated with schizophreniaAssessment of behaviorMulti-modal imaging studyPersistent psychosisPsychosis expressionCB1 receptorsCannabis exposureMemory encodingUse disorderPsychosisSchizophrenia